Drugs / mRNA-1273.815
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04927065 | May 2021 → Nov 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06354998 | Apr → May 2024 | Orthocoronavirinae infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05815498 | Mar 2023 → Apr 2025 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05436834 | Jun 2022 → Oct 2025 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1273.815 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06354998 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1273.815 vaccine” NCT05436834 ↗ |
| Route | Intramuscular | “Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.815 or 50 ug of mRNA-1273.231 on Day 1.” NCT04927065 ↗ |